BPC-157 Administration Routes in Research: What Studies Used

BPC-157 is a synthetic pentadecapeptide that has been studied mainly in animal models of gastrointestinal, tendon, ligament, muscle, bone, vascular and ocular injury. Because almost all of the published record is preclinical, questions about "routes" are really questions about laboratory methods: which delivery route researchers selected, why they selected it, and what the reviews said about whether the peptide survived that route. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question. Nothing below is a protocol, and no route described here is presented as something a reader should do.

Why route matters when reading this literature

Route determines how much of a peptide reaches tissue, how quickly, and whether a local or systemic effect is being tested. Reviews of the BPC-157 literature reported that investigators used several different routes across models and often reported comparable directional outcomes, which is one reason the peptide has been described in reviews as unusually route-tolerant (PMID 30915550, PMID 29998800). That description came from animal experiments, not from human pharmacokinetic comparisons. Recent clinical reviews reported that human data remain sparse and of low quality, so route-specific human bioavailability numbers are not established in this body of work (PMID 40756949, PMID 40789979).

Routes used in animal studies

Per-oral: intragastric gavage and drinking water

Reviews reported that rodent experiments most often used intragastric or drinking-water (per-oral) administration and intraperitoneal injection, with topical or local application at wound and soft-tissue sites also common (PMID 34267654, PMID 36551977). Researchers used gavage when a defined amount per body weight was needed at a defined time, and drinking-water administration when continuous exposure over days or weeks was the experimental question. Both are described in the literature as "per-oral" even though they differ substantially in timing and in how much each animal actually received.

Reviews of muscle and gastrointestinal models described this oral route as viable in part because the peptide was characterised as stable in human gastric juice, a property that is embedded in its common descriptor "stable gastric pentadecapeptide" (PMID 36551977, PMID 40573323). That stability claim is about resistance to degradation in gastric fluid; it is not the same as a measured oral bioavailability figure in humans.

Intraperitoneal injection

Intraperitoneal (IP) injection is standard in rodent pharmacology because it is fast, reproducible and avoids first-pass gastric handling. Reviews reported IP administration across models of vascular occlusion, ischaemia-reperfusion injury and organ dysfunction, where investigators wanted rapid systemic exposure after an acute insult (PMID 35125818, PMID 40573323). IP dosing has no direct human equivalent in routine practice, which is one reason reviewers cautioned against reading rodent results as transferable (PMID 40789979).

Subcutaneous, intramuscular and local injection at injury sites

In musculoskeletal models, researchers sometimes injected at or near the lesion — into or around a transected tendon, a crushed or transected muscle, or a bone defect — to test whether local delivery changed healing outcomes. Reviews of tendon, ligament, muscle and bone studies reported healing-related outcomes after both systemic and local application, and discussed angiogenic and growth-factor-related mechanisms as candidate explanations (PMID 29998800, PMID 30915550). Reviews of striated, smooth and heart muscle models similarly reported outcomes with local plus systemic regimens (PMID 36551977).

Searches about injecting a specific muscle, such as a biceps, do not map onto anything in this verified literature: the animal studies used standardised lesion models in rats and mice, and the reviews did not report controlled human trials of site-specific intramuscular injection for sports injuries (PMID 40756949).

Topical and other local application

Wound-healing reviews reported topical application at skin wound sites, including burns, incisions and fistulas, as a recurring method alongside systemic routes (PMID 34267654). In ocular research, reviews reported local application to the eye together with systemic administration in rat models of eye injury and intraocular pressure disturbance (PMID 37513963). Intranasal administration is sometimes discussed in non-academic sources, but it was not a documented route in the verified reviews summarised on this page; readers should treat it as unverified within this evidence set.

Routes at a glance: what the reviews described

The "empty stomach or with food" question

This is one of the most common searches about BPC-157, and the verified literature does not answer it. Reviews described the peptide as stable in gastric juice, which is the stated rationale for using per-oral routes in animals (PMID 40573323, PMID 36551977). But none of the reviews summarised here reported a fed-versus-fasted comparison, a food-effect study, or human absorption measurements by route. Rodent drinking-water protocols, by design, delivered peptide intermittently throughout the day alongside food intake, so they cannot be used to infer anything about fasting. Clinical reviewers instead emphasised the absence of human pharmacokinetic characterisation as a core gap (PMID 40756949).

Bioavailability findings by route: what reviews actually reported

The honest summary is that route-comparative bioavailability data are thin. Reviews of the preclinical record reported biological activity after oral, intraperitoneal, local and topical administration in animals, and framed this breadth as a notable feature of the molecule rather than as quantified absorption (PMID 29998800, PMID 34267654). A literature and patent review likewise catalogued a wide range of proposed applications and formulations across the patent record while noting that clinical development remained limited (PMID 40005999).

Mechanistic reviews reported that proposed pathways — angiogenic signalling, nitric oxide system modulation and interaction with growth-factor and neurotransmitter systems — were studied across multiple routes rather than being tied to one delivery method (PMID 40573323, PMID 38675421). Those remain preclinical mechanisms, not demonstrated human outcomes.

Human route reports: what exists

Human route reports are far scarcer than animal ones. Within this verified set, the available clinical example is intra-articular knee injection described in a small case series of patients with multiple types of knee pain, in which the authors reported symptom improvement (PMID 34324435). Case series lack control groups, blinding and randomisation, so this cannot establish efficacy, dose-response or route superiority. A 2025 systematic review of orthopaedic sports medicine applications reported that the evidence base was dominated by animal work and that controlled human trials were lacking (PMID 40756949), and a 2025 narrative review reached a similar conclusion while raising questions about unregulated use (PMID 40789979).

Injection-Site and Safety Observations: What Studies Report

Questions about pain after an injection are common, but the verified literature provides no systematic human safety dataset for any route. Preclinical reviews generally reported favourable tolerability signals in the animal models examined and discussed cytoprotective and safety-related pharmacology (PMID 40573323, PMID 34267654). Clinical reviewers were more cautious: they reported that human safety and long-term data were insufficient, that product quality and purity outside regulated manufacturing were uncertain, and that this combination limits any conclusion about risk (PMID 40789979, PMID 40756949). Injection-site reactions, sterility problems and pain are general risks of any injection procedure and are matters for a licensed clinician, not for a literature summary.

Regulatory context

BPC-157 is not an approved medicine in the United States, and reviews published in 2025 discussed its circulation outside conventional drug regulation alongside the shortage of controlled human trials (PMID 40789979, PMID 40005999). Material described as "research use only" is intended for laboratory work rather than human administration. This paragraph is regulatory background, not legal advice.

Limitations to keep in mind

• Species gap. Intraperitoneal and gavage routes are rodent laboratory techniques with no routine human counterpart (PMID 35125818).
• No route-comparison trials in humans. Reviews reported an absence of controlled human studies rather than negative findings (PMID 40756949).
• Publication concentration. Much of the preclinical corpus comes from a small number of research groups, a pattern noted in review discussions of evidence quality (PMID 40789979).
• Formulation opacity. Patent and literature reviews described many proposed formulations, but breadth of patents is not evidence of clinical performance (PMID 40005999).

In short, the study methods in this literature are diverse and the animal findings are directionally consistent across routes, while the human record is limited to small reports. Researchers chose routes to answer mechanistic questions in controlled models; those choices were not designed as guidance for people, and reviewers repeatedly reported that the translational step has not yet been taken.

References

• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025)
• Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Alternative Therapies in Health and Medicine, 2021)
• BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing (Current Pharmaceutical Design, 2018)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Current Reviews in Musculoskeletal Medicine, 2025)
• Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review (Pharmaceuticals, 2025)
• Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell and Tissue Research, 2019)
• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (Frontiers in Pharmacology, 2021)
• Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle (Biomedicines, 2022)
• Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System (Pharmaceuticals, 2025)
• Stable Gastric Pentadecapeptide BPC 157—Possible Novel Therapy of Glaucoma and Other Ocular Conditions (Pharmaceuticals, 2023)
• Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome (World Journal of Gastroenterology, 2022)
• The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity (Pharmaceuticals, 2024)